We conducted a clinical trial of thalidomide as initial therapy for asymptomatic smoldering (SMM) or indolent multiple myeloma (IMM). Sixteen patients were studied. Thalidomide was given orally at a dose of 200 mg/day for 2 weeks, and then increased as tolerated by 200 mg/day every 2 weeks to a maximum dose of 800 mg/day. Bone marrow microvessel density (MVD) and angiogenesis grading were estimated using CD34 immunostaining. Six patients had a confirmed response to therapy with at least 50% or greater reduction in serum and urine monoclonal (M) protein. When minor responses (25-49%) decrease in M protein concentration) were included, 11 of 16 patients (69%) responded to therapy. Major grade 3-4 toxicities included two patients with somnolence, and one patient each with syncope and neutropenia. Pre-treatment MVD was not a significant predictor of response to therapy, median MVD 4 and 12 in responders and non-responders respectively, P = 0.09. We conclude that thalidomide has significant activity in the treatment of newly diagnosed SMM/IMM. However, we do not recommend treatment with thalidomide at this stage since some patients with SMM/IMM can be stable for several months or years without any therapy. Additional randomized trials are needed to determine if thalidomide will delay progression to active multiple myeloma. Leukemia (2001Leukemia ( ) 15, 1274Leukemia ( -1276 
Introduction
Multiple myeloma (MM) is a clonal plasma cell proliferative disorder that accounts for 10% of malignant hematologic neoplasms. 1, 2 Not all patients with evidence of a clonal plasma cell proliferative disorder have active MM (Table 1) . Asympto- Table 1 Mayo Clinic criteria for the diagnosis of MGUS, SMM and MM
MGUS
Serum monoclonal protein Ͻ3 g/dl and bone marrow plasma cells Ͻ10% and absence of anemia, renal failure, hypercalcemia and lytic bone lesions SMM Serum monoclonal protein у3 g/dl and/or bone marrow plasma cells у10% and absence of anemia, renal failure, hypercalcemia and lytic bone lesions IMM Presence of a serum/urine monoclonal protein, bone marrow plasmacytosis, mild anemia or few small lytic bone lesions, and absence of symptoms MM Presence of a serum/urine monoclonal protein, bone marrow plasmacytosis and anemia, renal failure, hypercalcemia, or lytic bone lesions; patients with primary systemic amyloidosis and у30% bone marrow plasma cells are considered to have both multiple myeloma and amyloidosis MGUS, monoclonal gammopathy of undetermined significance; SMM, smoldering multiple myeloma; IMM, indolent multiple myeloma; MM, multiple myeloma. matic patients considered to have smoldering (SMM) or indolent myeloma (IMM) can be observed without treatment until evidence of progression. 3, 4 However, many of these patients do progress within a few years.
Recent evidence suggests that angiogenesis is increased in MM and has prognostic value in this disease. [5] [6] [7] Based on the increased angiogenesis observed in MM, thalidomide has been studied as potential anti-angiogenic therapy. Several trials show that thalidomide is active in 25-35% of patients with relapsed, refractory MM. 8, 9 Given the activity of thalidomide in advanced MM, we conducted a clinical trial of thalidomide in SMM and IMM.
Materials and methods

Eligibility
Patients were eligible to enter the study if they had previously untreated asymptomatic SMM or IMM as defined in Table 1 . Patients were required to have bone marrow (BM) plasma cells у10% and measurable disease defined as serum monoclonal (M) protein у2 g/dl and/or urine M protein у400 mg/24 h. Pregnant or nursing women, women of child-bearing potential who were unwilling to employ a dual method of contraception, and men who were unwilling to use a condom were not eligible for study. All patients gave written informed consent prior to enrollment on the study. Approval of the study and consent form by the Mayo Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki. All physicians prescribing the drug, and all study participants adhered to the requirements of the System for Thalidomide Education and Prescribing Safety (STEPS) program. Women of child-bearing age were required to have a pregnancy test done every 2 weeks while on study.
Treatment schedule
Thalidomide was given orally at a dose of 200 mg/day for 2 weeks, and then increased as tolerated by 200 mg/day every 2 weeks to a maximum dose of 800 mg/day. Patients were evaluated every 4 weeks for response. The dose of thalidomide was decreased as needed in the event of grade 2 or higher toxicity.
Response and toxicity criteria
The primary endpoint of this trial was confirmed response on two consecutive evaluations at least 4 weeks apart. Response was defined as reduction of serum and urine M protein by at least 50% accompanied by a similar reduction of soft tissue plasmacytomas if present. In addition, responses were categorized as a complete response (CR) if there was complete disappearance of monoclonal (M) protein in the serum and urine by immunofixation and absence of monoclonal plasma cells in the bone marrow. Disease progression was defined as a 50% increase in the M protein over the lowest response level. Increase in the size of existing lytic bony lesions or soft tissue plasmacytomas or appearance of new lytic bony lesions constituted progression. Disease that does not satisfy the criteria for response, complete response, or progression was categorized as stable disease. The National Cancer Institute Common toxicity criteria (Version 2) were used to grade adverse effects.
Laboratory correlative studies
BM angiogenesis was assessed using immunostaining for CD34 as previously described. 6, 7 Microvessel density (MVD) was estimated by determining the average number of vessels in three hot spots at 400 × magnification. BM angiogenesis was visually graded as low, intermediate and high. 6 
Statistical analysis
Ninety-five percent confidence intervals for the confirmed response probability was calculated using exact binomial 95% confidence intervals. Toxicity incidence was estimated and summarized using frequency and descriptive techniques to assess any patterns. The Fisher exact test was used to compare differences in nominal variables. For continuous variables, the rank-sum test was used for unpaired comparisons and the Wilcoxon signed rank test was used for paired comparisons. This interim report includes the first 16 patients treated on the study.
Results
Patient characteristics are described in Table 2 . The median age was 60 years (range, 38-75). The median serum M protein level prior to therapy was 3.2 g/dl (range, 0.3-6.8). The BM plasma cell percentage prior to therapy ranged from 10% to 45% (median, 28%).
Response
An objective response was seen in six patients for a confirmed response rate of 38% (95% confidence interval, 18-63%). If minor responses (25-49% reduction in M protein levels) were included, the response rate was 69%. Three patients had stable disease. In two patients, progressive disease occurred with no evidence of disease stabilization or response. The median response duration has not been reached after a median follow-up of 1 year. Responses in M protein levels were accompanied by a decrease in BM plasma cell percentage at 6 months and 1 year.
Toxicity
Therapy was generally well tolerated (Table 3 ). Major grade 3-4 toxicities included sedation in two patients, and neutropenia and syncope in one patient each. Common grade 1-2 toxicities included skin rash (44%), sedation (94%), constipation (94%), neuropathy (81%), anxiety (13%), and edema (13%). Grade 2 or higher toxicities were managed with 50% dose reduction. If required, the therapy was withheld until symptoms resolved and then restarted at a lower dose.
Response to therapy and angiogenesis
Angiogenesis grade was low, intermediate and high in 61, 31, and 8% of patients, respectively. BM microvessel density (MVD) prior to therapy ranged 2-30 per 400 × microscopic field (median, 7). Pre-treatment MVD was not significantly associated with response to therapy, median MVD 4 and 12 in responders and non-responders respectively, P = 0.09. None of the known prognostic factors for MM, including plasma cell labeling index predicted response to therapy. No significant changes were observed in MVD following treatment.
Discussion
Thalidomide was first introduced in clinical practice as a sedative in the late 1950s and subsequently withdrawn from the market in 1962 due to severe teratogenicity. It has made a remarkable comeback and is now FDA approved for the treatment of erythema nodosum leprosum (ENL). In the last 10 years, it has been studied and found to be useful in the treatment of AIDS-related cachexia, aphthous ulcers in patients with Behcet's disease and in the treatment of chronic graftversus-host disease. 7 Clinical trials in myeloma were initiated due to its anti-angiogenic properties, 10, 11 and based on evidence indicating a role for increased angiogenesis in the pathogenesis and progression of myeloma. 5, 12 Researchers at the University of Arkansas conducted a landmark trial Leukemia investigating the activity of thalidomide in relapsed myeloma. 8 They observed an overall response rate of 25% with a median time to response of 1 month. Several groups including ours have since confirmed the activity of thalidomide in relapsed, refractory myeloma. 9, 13, 14 The present study enrolled patients with previously untreated asymptomatic SMM and IMM. It demonstrates significant activity for single-agent thalidomide with an overall response rate of 38%. If minor responders (25-49% decrease in M protein) are included, the response rate is 69%. In the University of Arkansas study, the proportion of patients with relapsed myeloma who had reductions in paraprotein concentration by Ͼ25% was 32%. Thus the activity of thalidomide in SMM/IMM appears to be, as expected, better in previously untreated disease. MVD and other prognostic markers in myeloma failed to predict response to therapy.
Only one patient with SMM/IMM in this study had highgrade angiogenesis. This is much lower than the degree of angiogenesis reported in active MM. 5, 6, 15, 16 This suggests that BM angiogenesis is correlated with increased disease activity, and raises the question whether increased angiogenesis may have a pathogenetic role in the progression of SMM to MM. The finding that thalidomide has activity in SMM despite the fact that most patients had no evidence of increased BM angiogenesis, also raises questions about the mechanism of action of thalidomide in MM. In the Arkansas study, there were no statistically significant differences in post-treatment MVD change between responders and non-responders. 8 The present study confirms the same observations as well. Nevertheless, these findings may still not exclude an anti-angiogenic mechanism.
Thalidomide has other interesting properties that may be responsible for its activity. It inhibits the production of TNF␣ by enhancing the degradation of TNF␣ mRNA. 17 It stimulates cytotoxic T cell proliferation, and induces the secretion of interferon ␥ and IL-2 by these cells. 18 Thalidomide may also modulate the expression of several cell surface adhesion molecules. 19 Several research studies are underway to determine the mechanism of action of thalidomide in MM.
Patients with at least a 25% reduction in paraprotein concentration are continuing therapy beyond 1 year. The long-term follow-up of these patients will provide data on the durability of the responses and whether this strategy will significantly delay the time to progression to MM.
We conclude that thalidomide has significant activity in the treatment of newly diagnosed SMM/IMM. These patients are at significant risk for progression to active MM and it is important to identify non-myelosuppressive regimens that can delay or halt progression. However, we do not recommend treatment with thalidomide at this stage since some patients with SMM/IMM can be stable for several months or years without any therapy and this trial lacked a control arm. Randomized controlled trials are needed to determine if thalidomide will delay progression to MM and the need for chemotherapy and stem cell transplantation.
